Generics
Pre-eminent Leadership
Committed to uncompromised quality in products and services, New Age Pharmaceutical Company is an eminent supplier of essential medicines and specialty drugs to both public and private sectors in Hong Kong.
With its balanced and diversified product portfolio, the Group serves both the public and private sectors by its extensive market penetration covering substantially all of the public hospitals and clinics, private hospitals and registered pharmacies, private doctors and retail outlets in Hong Kong.
Leveraging our significant market presence and in-depth industry knowledge, we also work along with our overseas business partners to represent their products in Hong Kong, Macau, China and the Asia Pacific region for brand and market development.
Our large and growing portfolio allows us to compete with some of the key players in the industry as well as helps extend our presence into new markets.
-
BALANCED AND DIVERSIFIED GENERICS PORTFOLIO -
EXTENSIVE MARKET COVERAGE -
SERVING SUBSTANTIALLY ALL HOSPITALS AND OUT-PATIENT CLINICS -
LEADERSHIP IN A HOST OF HIGH GROWTH THERAPEUTIC CLASSES
ESSENTIAL MEDICINES
Supported by its robust integration of the pharmaceutical development, production, distribution and sales capabilities, New Age Pharmaceutical Company is a leading supplier of essential medicines in Hong Kong providing a comprehensive portfolio for healthcare professionals in both public and private sectors covering therapeutic categories such as cardiovascular, central nervous system, gastrointestinal, antidiabetic, respiratory, anti-infective, dermatological and anti-allergy.
SPECIALTY DRUGS
With the established strength in essential medicine offerings and operating a swift-to-market strategy through in-licensing, New Age Pharmaceutical Company also targets at expanding its portfolio and diversify into complex and specialty drugs, such as biosimilars, oncology medications, and orphan drugs, which have witnessed a robust growth trend driven by the advancement of healthcare.
The Group has also invested in projects to cement its position in the specialty drug market and collaborates with world-renowned research institutes for further expanding the indications of selected products.
VETERINARY MEDICINES
We believe that human health and animal health are closely connected in our shared environment. Animals for companionship has been a growing trend with the advancement of our society and the evolvement of lifestyle for various benefits and pursuits.
Catering to the growing demand for veterinary medicines and nutritional supplements, our veterinary health division and dedicated professional team support a network of over 1,000 veterinarians and 200 veterinary clinics in Hong Kong with a broad and expanding range for more than 400 existing products in different therapeutic classes and pharmaceutical forms.
We seek to foster our collaboration with the veterinary sector in advancing specialist care for animals, along with the products and services we provide, being backed by our comprehensive portfolio, professional team and GDP-accredited logistics and distribution facilities.
Regional Presence
Hub for Regional Coverage and Collaboration
In line with our vision and development, we continuously expand our footprints in certain strategic markets in Asia, entering into collaborative framework agreements with key partners in the region. Business development in the form of forging strategic partnership with local players in certain emerging markets is actively pursued.
Leveraging on its regional platform, New Age Pharmaceutical Company is well poised to collaborate strategically with reputable manufacturers globally through in-licensing, technology transfer or representation of finished branded products for expanding market presence in the Asia Pacific region such as China, Korea, Japan, Taiwan, Singapore, Malaysia, Cambodia, Myanmar, Thailand and Vietnam.
Located at the hub of the region, New Age Pharmaceutical Company is well positioned to provide a one-stop service and support to our partners across the Asian markets.